losmapimod
losmapimod: developed by 1 company · 3 clinical trials tracked.
losmapimod evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could losmapimod → FULC affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Fulcrum Therapeutics, Inc. (FULC) Facioscapulohumeral Muscular Dystrophy 1; Facioscapulohumera… | Phase 2 |
Clinical Trials (3)
A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
Primary endpoint: Part A: Change From Baseline in Total Relative Surface Area (RSA) Quadrants 1 to 5 (Q1-Q5) With 500 Grams (g) Wrist Weight Averaged Over Both Arms as Assessed by Reachable Workspace (RWS) at Week 48
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)
Primary endpoint: Number of Participants Reporting Serious Treatment Emergent Adverse Events (Serious TEAEs) and TEAEs
An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Subjects With Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) With Extension
Primary endpoint: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Frequently asked questions
Who is developing losmapimod?
losmapimod is being developed by Fulcrum Therapeutics, Inc..
How many clinical trials involve losmapimod?
BioSniper tracks 3 clinical trials involving losmapimod.